Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 66, Issue 3, Pages -Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/aac.02242-21
Keywords
antifungals; Candida auris; minimum inhibitory concentration; epidemiological cutoff
Categories
Funding
- WC
- New York State Department of Health (NYSDOH)
- CDC [NU50CK000516]
Ask authors/readers for more resources
Around 55% of U.S. Candida auris clinical cases were reported in New York and New Jersey from 2016 to 2020. Almost all clinical isolates from New York and New Jersey (99.8%) were resistant to fluconazole, and 50% were resistant to amphotericin B. Echinocandin resistance increased from 0% to 4%, and pan-resistance increased from 0 to C. auris clinical isolates, but not in New Jersey, highlighting regional differences.
About 55% of U.S. Candida auris clinical cases were reported from New York and New Jersey from 2016 through 2020. Nearly all New York-New Jersey clinical isolates (99.8%) were fluconazole resistant, and 50% were amphotericin B resistant. Echinocandin resistance increased from 0% to 4% and pan-resistance increased from 0 to C. auris clinical isolates but not for New Jersey, highlighting the regional differences. About 55% of U.S. Candida auris clinical cases were reported from New York and New Jersey from 2016 through 2020. Nearly all New York-New Jersey clinical isolates (99.8%) were fluconazole resistant, and 50% were amphotericin B resistant. Echinocandin resistance increased from 0% to 4% and pan-resistance increased from 0 to C. auris clinical isolates but not for New Jersey, highlighting the regional differences.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
